Nat Turner, co-founder and CEO of Flatiron Health, discusses how oncologists use data to assist them in meeting the requirements in new payment models.
Nat Turner, co-founder and CEO of Flatiron Health, discusses how oncologists use data to assist them in meeting the requirements in new payment models.
Transcript (slightly modified)
How are oncologists using data to help them meet the requirements in new payment models?
There are some simple things and some complicated things. The simplest ones—our software has the care plan built-in, so the IOM [Institute of Medicine] care plan physician doesn’t have to think about it. It auto-populates an OncoEMR, you can print it right there, the patient can be in the room, and done. A lot of analytics—getting a little more complicated but very important—analytics around how many patients do I have that are potentially eligible for the episode, which of my physicians are appropriately completing the care plan for the appropriate patients?
Getting a little more sophisticated quality measures—these are very complicated measures, some of them are easy and some are pretty hard. It takes a lot of manual work if you are going to do it on your own, to be compliant and provide the data. Some of them you have to track and some of them Medicare tracks for you. We help you in both.
So, the software is basically automating the quality measure process and moving it to the more sophisticated realm is more analytics around: what is your cost of care? What are the opportunities to implement programs that could reduce cost? For example, in hospital admissions or ER visits—more deeper analytics to help you transform your practice. Those are kind of the levels.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More